The main types of diseases and clinical applications treated by tazetostat (Davico)

Tazemetostat (Tazemetostat) is an oral small molecule targeted drug. Its main mechanism of action is to inhibit the activity of EZH2 (enhancer homolog 2) enzyme. EZH2 is a methyltransferase related to epigenetic regulation. It is overexpressed or mutated in some tumors, thereby promoting cancer cell proliferation and malignant transformation. By selectively inhibiting EZH2, tazerestat can reverse abnormal epigenetic modifications, thereby inhibiting the growth and spread of tumor cells and providing a new treatment method for some patients with refractory tumors.

Among the clinically approved indications, tazerestat is mainly used to treat locally advanced or metastatic epithelioid sarcoma (epithelioid sarcoma). This type of tumor is relatively rare, and most patients are young. Traditional chemotherapy and radiotherapy have limited effects, and treatment options are scarce. The application of tazetostat has significantly improved the disease control rate and delayed the progression of the disease in some patients, providing new hope for these patients. In addition, tazerestat has also been approved for the treatment of relapsed or refractory follicular lymphoma (follicular lymphoma), especially for patients carrying EZH2 gene mutations. The response rate is significantly higher than that of people without mutations, reflecting the value of precision medicine.

Currently, tazerestat is also undergoing clinical research in multiple tumor areas, including diffuse largeB cell lymphoma (DLBCL), rhabdomyosarcoma and multiple myeloma. Preliminary research shows that tazerestat exhibits good anti-tumor activity in some patients with EZH2 mutations or epigenetic abnormalities, further broadening its potential application space. This drug not only brings breakthroughs in rare tumors, but also promotes the application of epigenetics in the field of tumor treatment.

Overall, tazerestat provides a new treatment option for epithelioid sarcoma and some EZH2 mutation-associated lymphomas. Although the current indications are limited, its application scope is expected to continue to expand as research deepens. During clinical use, patients should undergo genetic testing and efficacy evaluation under the guidance of doctors in order to rationally select the population and maximize the clinical value of the drug.

Reference materials:https://www.drugs.com/